報價延遲最少15分鐘:2026/04/22 22:47 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
7.73 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.02/-0.17
|
|
企業價值
718.94M
|
| 資產負債 |
|
每股賬面淨值
1.16
|
| 現金流量 |
|
現金流量率
0.00
|
| 損益表 |
|
收益
116.59M
|
|
每股收益
1.11
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liverfibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other. |
